Amlodipine Besylate/Fimasartan Potassium

苯磺酸氨氯地平/非马沙坦钾

Report date: 2022/03/08 16:47:01

Base Information

Drug NameAmlodipine Besylate/Fimasartan Potassium
Drug Alias NameAmlodipine/Fimasartan Potassium氨氯地平/非马沙坦钾Amlodipine/Fimasartan非马沙坦钾/苯磺酸氨氯地平Amlodipine Besylate and Fimasartan Potassium +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsEssential Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2016/08/09
Country/TerritorySouth Korea
CombinationsYes Fimasartan Potassium TrihydrateAmlodipine Besylate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoryung Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential Hypertension
Inactive IndicationsHypertension

Other Information

ATC CodeC09DB09
Related LinksN/A